Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol 1,648
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 84%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provid...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3817 3700
Address:
4-6-10, Koishikawa, Bunkyo-ku, Tokyo, Japan
Latest News on ESALF
No data available.